Ehab Rasmy Bendas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ehab Rasmy Bendas has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Emad B. Basalious
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
3 shared publications Magdy I. Mohamed
3 shared publications- Mamdouh R. Rezk
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
3 shared publications - Enas Ahmed Mahmoud
University of California
2 shared publications Iman A. Karim
Advanced Research Center (ARC), Nasr City, Cairo, Egypt
2 shared publicationsJ. Mark Christensen
Department of Pharmaceutics, College of Pharmacy, Oregon State University, Corvallis, OR, USA
2 shared publications
Latest Publications
- 23 July 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (9) , 547-556
Intraperitoneal Granisetron for Post‐Laparoscopic Cholecystectomy Pain Management: A Double‐Blinded, Randomized Controlled Trial
Background: Laparoscopic cholecystectomy (LC) may cause significant pain, increasing morbidity. Granisetron, an antiemetic selective serotonin (5HT3)‐antagonist, demonstrates analgesic properties through sodium channel blockade. The current study aims to assess the efficacy of adjuvant intraperitoneal granisetron in post‐LC pain. Research Design and Methods: In this prospective randomized controlled trial, 48 patients undergoing LC were randomized into placebo (intraperitoneal saline) and intervention (intraperitoneal granisetron) groups. Pain intensity was measured via visual analog scale (VAS) at 2‐, 4‐, 8‐, 12‐, and 24‐h post‐surgery, with comparative analysis of the area under the curve (AUC) of the 24‐h VAS scores. Additional outcomes included sedation levels, persistent pain incidence, quality of life improvement, postoperative nausea and vomiting (PONV), time to first rescue analgesic request, total analgesic consumption, and independent mobilization. Results: The treatment group showed significantly lower VAS at 8, 12, and 24 h ( p = 0.039, 0.004, 0.030) and lower VAS score AUC (542.7 ± 260.5 vs. 767.1 ± 317.8, p = 0.011) compared to controls, respectively. No significant differences were observed in (2–4 h) pain scores, persistent pain incidence, quality of life, sedation levels, PONV, analgesic requirements, or mobilization time ( p < 0.05). Conclusions: Granisetron could improve multimodal pain control after LC, offering better outcomes while maintaining its established safety profile. Trial Registration: NCT06281418
- 23 July 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (9) , 547-556
Intraperitoneal Granisetron for Post‐Laparoscopic Cholecystectomy Pain Management: A Double‐Blinded, Randomized Controlled Trial
Background: Laparoscopic cholecystectomy (LC) may cause significant pain, increasing morbidity. Granisetron, an antiemetic selective serotonin (5HT3)‐antagonist, demonstrates analgesic properties through sodium channel blockade. The current study aims to assess the efficacy of adjuvant intraperitoneal granisetron in post‐LC pain. Research Design and Methods: In this prospective randomized controlled trial, 48 patients undergoing LC were randomized into placebo (intraperitoneal saline) and intervention (intraperitoneal granisetron) groups. Pain intensity was measured via visual analog scale (VAS) at 2‐, 4‐, 8‐, 12‐, and 24‐h post‐surgery, with comparative analysis of the area under the curve (AUC) of the 24‐h VAS scores. Additional outcomes included sedation levels, persistent pain incidence, quality of life improvement, postoperative nausea and vomiting (PONV), time to first rescue analgesic request, total analgesic consumption, and independent mobilization. Results: The treatment group showed significantly lower VAS at 8, 12, and 24 h ( p = 0.039, 0.004, 0.030) and lower VAS score AUC (542.7 ± 260.5 vs. 767.1 ± 317.8, p = 0.011) compared to controls, respectively. No significant differences were observed in (2–4 h) pain scores, persistent pain incidence, quality of life, sedation levels, PONV, analgesic requirements, or mobilization time ( p < 0.05). Conclusions: Granisetron could improve multimodal pain control after LC, offering better outcomes while maintaining its established safety profile. Trial Registration: NCT06281418
- Open Access
- 28 November 2024
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 10 (1) , 1-13
Different approaches in management of neonatal unconjugated hyperbilirubinemia: a review article
Background: Neonatal hyperbilirubinemia is a prevalent condition that affects newborns, characterized by elevated serum bilirubin levels. The accumulation of bilirubin can cause neurotoxicity, resulting in various complications, and in severe cases, even mortality. The underlying pathophysiology of this condition primarily involves an inconsistency between the synthesis and excretion of bilirubin. Despite the short- and long-term side effects of phototherapy, it is considered a core treatment of neonatal hyperbilirubinemia. Exchange transfusion is considered a last resort in cases where phototherapy fails. Several studies have investigated the use of various agents either to replace phototherapy or to be added as adjuvants to reduce the time required for phototherapy and hence minimize the adverse effects. Some of these studies have demonstrated positive outcomes, indicating their effectiveness, while others have failed to yield any significant differences in treatment duration. Main text: The present review summarized the etiology of neonatal hyperbilirubinemia. It was demonstrated that neonatal hyperbilirubinemia has mainly two types: Conjugated and unconjugated hyperbilirubinemia. Treatment options for neonatal hyperbilirubinemia were discussed with phototherapy as the most prevalent and successful option followed by exchange transfusion. Side effects of phototherapy were also discussed together with the different approaches introduced to clinical practice to minimize these side effects. Conclusion: Phototherapy is the most successful treatment of neonatal hyperbilirubinemia, although its side effects are of great concern. Studies introducing adjuvants such as zinc sulfate and ursodeoxycholic acid have demonstrated promising results in reducing the duration of phototherapy and minimizing the side effects. However, these results are inconclusive, and further research is required to validate the safety and efficacy of these adjuvants.
- 28 November 2024
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 10 (1) , 1-13
Open AccessDifferent approaches in management of neonatal unconjugated hyperbilirubinemia: a review article
Background: Neonatal hyperbilirubinemia is a prevalent condition that affects newborns, characterized by elevated serum bilirubin levels. The accumulation of bilirubin can cause neurotoxicity, resulting in various complications, and in severe cases, even mortality. The underlying pathophysiology of this condition primarily involves an inconsistency between the synthesis and excretion of bilirubin. Despite the short- and long-term side effects of phototherapy, it is considered a core treatment of neonatal hyperbilirubinemia. Exchange transfusion is considered a last resort in cases where phototherapy fails. Several studies have investigated the use of various agents either to replace phototherapy or to be added as adjuvants to reduce the time required for phototherapy and hence minimize the adverse effects. Some of these studies have demonstrated positive outcomes, indicating their effectiveness, while others have failed to yield any significant differences in treatment duration. Main text: The present review summarized the etiology of neonatal hyperbilirubinemia. It was demonstrated that neonatal hyperbilirubinemia has mainly two types: Conjugated and unconjugated hyperbilirubinemia. Treatment options for neonatal hyperbilirubinemia were discussed with phototherapy as the most prevalent and successful option followed by exchange transfusion. Side effects of phototherapy were also discussed together with the different approaches introduced to clinical practice to minimize these side effects. Conclusion: Phototherapy is the most successful treatment of neonatal hyperbilirubinemia, although its side effects are of great concern. Studies introducing adjuvants such as zinc sulfate and ursodeoxycholic acid have demonstrated promising results in reducing the duration of phototherapy and minimizing the side effects. However, these results are inconclusive, and further research is required to validate the safety and efficacy of these adjuvants.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S20)
Wireless Dosage Monitoring for Donepezil Transdermal Patches as a Novel Concept
Remote therapy, also known as teletherapy or online therapy, refers to the provision of mental health services through electronic means, such as phone, text, or video conferencing. With the advent of the internet and other digital technologies, it has become increasingly possible for therapists and patients to interact remotely, without the need for in‐person visits.Remote therapy has gained popularity in recent years, particularly during the COVID‐19 pandemic, as it allows individuals to access mental health support from the safety and convenience of their own homes. It is also a useful option for those who live in rural or underserved areas, where access to in‐person therapy may be limited.Donepezil (cholinesterase inhibitor) is effective for improving the cognitive and global functioning of patients with Alzheimer’s disease. This drug was formulated as transdermal patch by the ethanol based nano carrier & micro gas sensor. Our work intends to create a simple approach to administer Donepezil systemically by applying a transdermal patch, as well as a practical monitoring technique by employing a gas sensor that collects data and wirelessly transmits it to cell phone application. The application depends on short massage services. Wireless technology offers several advantages, including improved data mobility and data transfer via various methods such as Wi‐Fi, internet connection, or Bluetooth to enable continuous medical monitoring. The sensor has the advantages of being small, not battery operated and delivering doses without human interference that reduces error, making the technique favorable for elderly and mentally disabled patients. This innovative technology permits the physician to monitor the drug level in the patch and give an alarm for applying the next doses through cell phone application.In conclusion, remote therapy using the transdermal route of administration is a valuable option for individuals suffering from cognitive disease like Alzheimer’s Disease because it avoids first‐pass effects, reduces adverse symptoms associated with the oral route, and increases the economic benefits of using the correct doses when needed.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S20)
Open AccessWireless Dosage Monitoring for Donepezil Transdermal Patches as a Novel Concept
Remote therapy, also known as teletherapy or online therapy, refers to the provision of mental health services through electronic means, such as phone, text, or video conferencing. With the advent of the internet and other digital technologies, it has become increasingly possible for therapists and patients to interact remotely, without the need for in‐person visits.Remote therapy has gained popularity in recent years, particularly during the COVID‐19 pandemic, as it allows individuals to access mental health support from the safety and convenience of their own homes. It is also a useful option for those who live in rural or underserved areas, where access to in‐person therapy may be limited.Donepezil (cholinesterase inhibitor) is effective for improving the cognitive and global functioning of patients with Alzheimer’s disease. This drug was formulated as transdermal patch by the ethanol based nano carrier & micro gas sensor. Our work intends to create a simple approach to administer Donepezil systemically by applying a transdermal patch, as well as a practical monitoring technique by employing a gas sensor that collects data and wirelessly transmits it to cell phone application. The application depends on short massage services. Wireless technology offers several advantages, including improved data mobility and data transfer via various methods such as Wi‐Fi, internet connection, or Bluetooth to enable continuous medical monitoring. The sensor has the advantages of being small, not battery operated and delivering doses without human interference that reduces error, making the technique favorable for elderly and mentally disabled patients. This innovative technology permits the physician to monitor the drug level in the patch and give an alarm for applying the next doses through cell phone application.In conclusion, remote therapy using the transdermal route of administration is a valuable option for individuals suffering from cognitive disease like Alzheimer’s Disease because it avoids first‐pass effects, reduces adverse symptoms associated with the oral route, and increases the economic benefits of using the correct doses when needed.
- 24 April 2023
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 73 (06) , 349-354
Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation
Favipiravir is an antiviral drug used to treat influenza and is also being investigated for the treatment of SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release tablets. In vitro dissolution testing was investigated for favipiravir tablets in three different pH media. The pharmacokinetic features of favipiravir were examined in 27 healthy male Egyptian volunteers. The parameter “AUC0-t” vs. percent dissolved was used to develop level C in vitro in vivo correlation (IVIVC) to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets. The in vitro release results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cpmax of 5966.45 ng/mL at median tmax of 0.75 h with AUC0-∞ equals 13325.54 ng.h/mL, showing half-life of 1.25 h. Level C IVIVC was developed successfully. It was concluded that Egyptian volunteers had comparable Pk values to American and Caucasian volunteers, however they were considerably different from Japanese subjects. AUC0-t vs. % dissolved was used to develop level C IVIVC to set the optimum dissolution medium. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.
- 24 April 2023
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 73 (06) , 349-354
Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation
Favipiravir is an antiviral drug used to treat influenza and is also being investigated for the treatment of SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release tablets. In vitro dissolution testing was investigated for favipiravir tablets in three different pH media. The pharmacokinetic features of favipiravir were examined in 27 healthy male Egyptian volunteers. The parameter “AUC0-t” vs. percent dissolved was used to develop level C in vitro in vivo correlation (IVIVC) to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets. The in vitro release results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cpmax of 5966.45 ng/mL at median tmax of 0.75 h with AUC0-∞ equals 13325.54 ng.h/mL, showing half-life of 1.25 h. Level C IVIVC was developed successfully. It was concluded that Egyptian volunteers had comparable Pk values to American and Caucasian volunteers, however they were considerably different from Japanese subjects. AUC0-t vs. % dissolved was used to develop level C IVIVC to set the optimum dissolution medium. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.
- Open Access
- 22 August 2022
- Published by Springer Nature in Research Square
Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy EgyptianVolunteers and Development of Level C In-vitro In-vivo Correlation
Background and ObjectiveFavipiravir is an antiviral drug used to treat influenza. It is also being investigated for the treatment of a variety of other viral diseases, including SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic (Pk) features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release (IR) tablets.MethodsIn vitrodissolution testing was investigated for favipiravir tablet, Avigan®200 mg tablets, in three different pH media. The pharmacokinetic (Pk) features of favipiravir were examined in healthy male Egyptian volunteers. A newly developed and validated LC-MS/MS method was used to analyze real plasma samples of the healthy volunteers. Level Cin vitro in vivocorrelation (IVIVC) was developed to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets.ResultsIn vitro dissolution results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cpmaxof 5966.45ng/mL at median tmaxof 0.75 h with AUC0-∞equals 13325.54 ng.h/mL, showing half-life of 1.25 h. AUC0-tvs. % dissolved was used to develop level C IVIVC for favipiravir (IR) tablets.ConclusionsWhen compared to American and Caucasian volunteers, Egyptian participants had comparable Pk values, however they were considerably different from Japanese subjects. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.
- 22 August 2022
- Published by Springer Nature in Research Square
Open AccessDoes the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy EgyptianVolunteers and Development of Level C In-vitro In-vivo Correlation
Background and ObjectiveFavipiravir is an antiviral drug used to treat influenza. It is also being investigated for the treatment of a variety of other viral diseases, including SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic (Pk) features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release (IR) tablets.MethodsIn vitrodissolution testing was investigated for favipiravir tablet, Avigan®200 mg tablets, in three different pH media. The pharmacokinetic (Pk) features of favipiravir were examined in healthy male Egyptian volunteers. A newly developed and validated LC-MS/MS method was used to analyze real plasma samples of the healthy volunteers. Level Cin vitro in vivocorrelation (IVIVC) was developed to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets.ResultsIn vitro dissolution results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cpmaxof 5966.45ng/mL at median tmaxof 0.75 h with AUC0-∞equals 13325.54 ng.h/mL, showing half-life of 1.25 h. AUC0-tvs. % dissolved was used to develop level C IVIVC for favipiravir (IR) tablets.ConclusionsWhen compared to American and Caucasian volunteers, Egyptian participants had comparable Pk values, however they were considerably different from Japanese subjects. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.
- Open Access
- 1 January 2019
- Published by Elsevier in Journal of Advanced Research
- Vol. 15, 37-47
A new design for a chronological release profile of etodolac from coated bilayer tablets: In-vitro and in-vivo assessment
- 1 January 2019
- Published by Elsevier in Journal of Advanced Research
- Vol. 15, 37-47
Open AccessA new design for a chronological release profile of etodolac from coated bilayer tablets: In-vitro and in-vivo assessment
- 7 February 2018
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 38 (5) , 439-448
Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers
The purpose of this study was to apply the reference-scaled average bioequivalence (RSABE) approach to evaluate the bioequivalence and to investigate the pharmacokinetic properties of two formulations of fixed dose combination (FDC) tablet of sofosbuvir (SOF) and ledipasvir (LED) (400/90 mg) in 36 healthy Egyptian volunteers.
- 7 February 2018
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 38 (5) , 439-448
Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers
The purpose of this study was to apply the reference-scaled average bioequivalence (RSABE) approach to evaluate the bioequivalence and to investigate the pharmacokinetic properties of two formulations of fixed dose combination (FDC) tablet of sofosbuvir (SOF) and ledipasvir (LED) (400/90 mg) in 36 healthy Egyptian volunteers.
- Open Access
- 14 December 2017
- Published by Taylor & Francis in Drug Delivery
- Vol. 25 (1) , 78-90
Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study
Solid lipid nanoparticles (SLNs) are very potential formulations for topical delivery of antifungal drugs. Hence, the purpose of this research was to formulate the well-known antifungal agent Fluconazole (FLZ)-loaded SLNs topical gel to improve its efficiency for treatment of Pityriasis Versicolor (PV). FLZ-SLNs were prepared by modified high shear homogenization and ultrasonication method using different concentration of solid lipid (Compritol 888 ATO, Precirol ATO5) and surfactant (Cremophor RH40, Poloxamer 407). The physicochemical properties and the in vitro release study for all FLZ-SLNs were investigated. Furthermore, the optimized FLZ-SLN formula was incorporated into gel using Carpobol 934. A randomized controlled clinical trial (RCT) of potential batches was carried out on 30 well diagnosed PV patients comparing to market product Candistan® 1% cream. Follow up was done for 4 weeks by clinical and KOH examinations. The results showed that FlZ-SLNs were almost spherical shape having colloidal sizes with no aggregation. The drug entrapment efficiency ranged from 55.49% to 83.04%. The zeta potential values lie between -21 and -33 mV presenting good stability. FLZ showed prolonged in vitro release from SLNs dispersion and its Carbapol gel following Higuchi order equation. Clinical studies registered significant improvement (p < .05) in therapeutic response (1.4-fold; healing%, 4-fold; complete eradication) in terms of clinical cure and mycological cure rate from PV against marketed cream. Findings of the study suggest that the developed FLZ loaded SLNs topical gels have superior significant fast therapeutic index in treatment of PV over commercially available Candistan® cream.
- 14 December 2017
- Published by Taylor & Francis in Drug Delivery
- Vol. 25 (1) , 78-90
Open AccessFluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study
Solid lipid nanoparticles (SLNs) are very potential formulations for topical delivery of antifungal drugs. Hence, the purpose of this research was to formulate the well-known antifungal agent Fluconazole (FLZ)-loaded SLNs topical gel to improve its efficiency for treatment of Pityriasis Versicolor (PV). FLZ-SLNs were prepared by modified high shear homogenization and ultrasonication method using different concentration of solid lipid (Compritol 888 ATO, Precirol ATO5) and surfactant (Cremophor RH40, Poloxamer 407). The physicochemical properties and the in vitro release study for all FLZ-SLNs were investigated. Furthermore, the optimized FLZ-SLN formula was incorporated into gel using Carpobol 934. A randomized controlled clinical trial (RCT) of potential batches was carried out on 30 well diagnosed PV patients comparing to market product Candistan® 1% cream. Follow up was done for 4 weeks by clinical and KOH examinations. The results showed that FlZ-SLNs were almost spherical shape having colloidal sizes with no aggregation. The drug entrapment efficiency ranged from 55.49% to 83.04%. The zeta potential values lie between -21 and -33 mV presenting good stability. FLZ showed prolonged in vitro release from SLNs dispersion and its Carbapol gel following Higuchi order equation. Clinical studies registered significant improvement (p < .05) in therapeutic response (1.4-fold; healing%, 4-fold; complete eradication) in terms of clinical cure and mycological cure rate from PV against marketed cream. Findings of the study suggest that the developed FLZ loaded SLNs topical gels have superior significant fast therapeutic index in treatment of PV over commercially available Candistan® cream.
- 22 November 2016
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 16 (3) , 358-363
Assessment of cubosomal alpha lipoic acid gel efficacy for the aging face: a single‐blinded, placebo‐controlled, right‐left comparative clinical study
Summary: Background: A poloxamer solution acting as a vehicle for the lipid base particulate system (cubosome dispersions) containing alpha lipoic acid (ALA) has achieved encouraging results in skin aging.Objective: Evaluate the efficacy of 5% Cubosomal ALA as an anti‐aging formulation.Methods: This single‐blinded, placebo‐controlled, comparative study was conducted on 20 females. Patients were instructed to apply a gel formulation containing the active ingredient over the right half of their face and a placebo gel on the left half twice daily for 6 months. Global aesthetic improvement scale (GAIS) was utilized as a measure of clinical progress. The thicknesses of the epidermis and dermis were assessed before and after treatment using an ultrasound biomicroscope.Results: The GAIS score assessment at 3 and 6 months showed a significantly greater improvement on the right sides in comparison with the left sides. At the end of the treatment period, the mean epidermal thickness significantly increased on the right side in comparison with the left side and the mean dermal thickness increased more on the right side in comparison with the left side; however, this difference was not significant.Conclusion: 5% Cubosomal ALA is an effective and safe modality for improving aging face.
- 22 November 2016
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 16 (3) , 358-363
Assessment of cubosomal alpha lipoic acid gel efficacy for the aging face: a single‐blinded, placebo‐controlled, right‐left comparative clinical study
Summary: Background: A poloxamer solution acting as a vehicle for the lipid base particulate system (cubosome dispersions) containing alpha lipoic acid (ALA) has achieved encouraging results in skin aging.Objective: Evaluate the efficacy of 5% Cubosomal ALA as an anti‐aging formulation.Methods: This single‐blinded, placebo‐controlled, comparative study was conducted on 20 females. Patients were instructed to apply a gel formulation containing the active ingredient over the right half of their face and a placebo gel on the left half twice daily for 6 months. Global aesthetic improvement scale (GAIS) was utilized as a measure of clinical progress. The thicknesses of the epidermis and dermis were assessed before and after treatment using an ultrasound biomicroscope.Results: The GAIS score assessment at 3 and 6 months showed a significantly greater improvement on the right sides in comparison with the left sides. At the end of the treatment period, the mean epidermal thickness significantly increased on the right side in comparison with the left side and the mean dermal thickness increased more on the right side in comparison with the left side; however, this difference was not significant.Conclusion: 5% Cubosomal ALA is an effective and safe modality for improving aging face.